Ethosuximide NDC 62135-064

NDC codes

FDA NDC Directory

Product NDC (as listed)62135-064Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62135-0064Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
62135-064-47	62135006447	473 mL in 1 BOTTLE (62135-064-47)Marketed from May 20, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ethosuximide
Generic name (nonproprietary): ethosuximide
Active ingredients: Ethosuximide — 250 mg/5mL
Dosage form: Solution
Route: Oral
Labeler: Chartwell RX, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 040506
Marketing start: Dec 22, 2003
Listing expires: Dec 31, 2027
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 62135-064_52e254a5-0329-2dda-e063-6294a90aa082SPL ID 52e254a5-0329-2dda-e063-6294a90aa082SPL set ID 9812840a-004d-46fa-8414-7d04a384e06aRxCUI 251322UNII 5SEH9X1D1DUPC 0362135064471
Pharmacologic class: Anti-epileptic Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N462135006447 followed by a unit qualifier and the quantity

Package 62135-0064-47. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 28, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Ethosuximide is indicated for the control of absence (petit mal) epilepsy.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 040506

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 040506
Product	Strength	Form · route	Labeler	Product NDC
Ethosuximide	Ethosuximide 250 mg/5mL	SolutionOral	Chartwell Governmental & Specialty RX, LLC.	68999-064